Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM2: Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated NSCLC After Osimertinib
NCT07379476Phase 2
Key facts
- Status
- Recruiting
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Countries
- 1
- Sponsor
- The Chinese University of Hong Kong
- Modality
- Small Molecules
- Drugs
- osimertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Progression-Free Survival at 2 years. Started Feb 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Radiotherapy arm
Continue osimertinib + Local ablative therapy
Control arm
Continue osimertinib alone
03
Who it enrols
Adults with stage IV NSCLC harboring EGFR exon 19 deletion or L858R mutation, who have received 12-24 weeks of first-line osimertinib with no disease progression and have <=3 active oligoresidual sites amenable to local ablative therapy.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Adverse Events
Time to Treatment Failure
Site of tumour progression
Beyond the preview
Go deeper on NCT07379476.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379476.